{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:57:07Z","timestamp":1773435427705,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp;amp; Perspec"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first\u2010line antiviral agents for chronic hepatitis B (CHB), yet comparative real\u2010world data in Southeast Asian populations remain limited. This retrospective cohort study aimed to compare the efficacy, biochemical response, antifibrotic effect, and renal safety of TDF versus ETV in treatment\u2010na\u00efve Vietnamese patients with CHB over a 48\u2010week period. A total of 348 patients (TDF: 181; ETV: 167) were included and evaluated at baseline, Weeks 12, 24, and 48. Both groups demonstrated comparable virologic suppression at Week 48 (TDF: 58.0%, ETV: 52.1%, <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). TDF achieved significantly higher ALT normalization at Week 24 (72.9% vs. 59.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.01) and Week 48 (84.0% vs. 69.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). In contrast, ETV led to faster AST normalization and greater early reductions in APRI and FIB\u20104 at Week 12. Renal function mildly declined in the TDF group (mean eGFR change: \u22123.84\u2009\u00b1\u200911.98, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) but improved in the ETV group (+3.02\u2009\u00b1\u200912.34, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Both treatments were well tolerated with no virologic breakthrough or serious adverse events. In conclusion, both TDF and ETV offer effective antiviral therapy for Vietnamese CHB patients. TDF may be preferable in patients with active hepatic inflammation, whereas ETV may benefit those with baseline renal concerns or early fibrotic progression. These findings support a tailored approach to HBV management based on individual patient profiles.<\/jats:p>","DOI":"10.1002\/prp2.70177","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:39:49Z","timestamp":1759408789000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Efficacy and Renal Safety of Entecavir and Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B: A Retrospective Cohort Study From Vietnam"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-7861","authenticated-orcid":false,"given":"Thong Duy","family":"Vo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, School of Medicine University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"},{"name":"Department of Gastroenterology University Medical Center Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Ngoc Gia","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang The","family":"Phan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Medical Center Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization \u201cHepatitis B. WHO Fact Sheets \u201d(2023)."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"6","key":"e_1_2_11_5_1","article-title":"2\u2010Year GLOBE Trial Results: Entecavir vs Lamivudine in HBeAg\u2010Positive Patients","volume":"43","author":"Liaw Y. F.","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23785"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61425-1"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4070"},{"issue":"4","key":"e_1_2_11_9_1","first-page":"836","article-title":"Comparison of Biochemical Response and Renal Safety of Entecavir vs Tenofovir in Treatment\u2010Na\u00efve Chronic Hepatitis B Patients","volume":"40","author":"Park J. Y.","year":"2020","journal-title":"Liver International"},{"issue":"1","key":"e_1_2_11_10_1","first-page":"58","article-title":"Comparison of Entecavir and Tenofovir on the Development of Hepatocellular Carcinoma in Treatment\u2010Na\u00efve Patients With Chronic Hepatitis B. A Nationwide Cohort Study","volume":"27","author":"Lee S. W.","year":"2020","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"e_1_2_11_11_1","first-page":"1021","article-title":"Hepatitis B Virus Infection in Vietnam: A Call for Improved Access to Diagnosis and Treatment","volume":"42","author":"Nguyen V. H.","year":"2022","journal-title":"Liver International"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000749"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S309311"},{"issue":"6","key":"e_1_2_11_14_1","first-page":"1462","article-title":"Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Chronic Hepatitis B Patients in a Territory\u2010Wide Cohort","volume":"71","author":"Yip T. C.","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"e_1_2_11_15_1","first-page":"597","article-title":"Long\u2010Term Renal Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients With Compensated Liver Cirrhosis","volume":"28","author":"Tsai M. C.","year":"2021","journal-title":"Journal of Viral Hepatitis"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.118721"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:07:04Z","timestamp":1760980024000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/prp2.70177"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70177","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70177"}}